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Abstract
Alcohol and drug use disorders are individually heritable (50%). Twin studies indicate that alcohol 
and substance use disorders share common genetic influences, and therefore may represent a more 
heritable form of addiction and thus be more powerful for genetic studies. This study utilized data 
from 2,322 subjects from 118 European-American families in the COGA sample to conduct 
genomewide association analysis of a binary and a continuous index of general substance 
dependence liability. The binary phenotype (ANYDEP) was based on meeting lifetime criteria for 
any DSM-IV dependence on alcohol, cannabis, cocaine or opioids. The quantitative trait 
(QUANTDEP) was constructed from factor analysis based on endorsement across the 7 DSM-IV 
criteria for each of the 4 substances. Heritability was estimated to be 54% for ANYDEP and 86% 
for QUANTDEP. One SNP, rs2952621 in the uncharacterized gene LOC151121 on chromosome 
2, was associated with ANYDEP (p=1.8×10−8), with support from surrounding imputed SNPs and 
replication in an independent sample (SAGE; p=0.02). One SNP, rs2567261 in ARHGAP28 (Rho 
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GTPase activating protein 28), was associated with QUANTDEP (p=3.8×10−8), and supported by 
imputed SNPs in the region, but did not replicate in an independent sample (SAGE; p=0.29). The 
results of this study provide evidence that there are common variants that contribute to the risk for 
a general liability to substance dependence.
Keywords
alcohol dependence; cannabis dependence; cocaine dependence; common genetic liability; drug 
dependence; opioid dependence
INTRODUCTION
An estimated 15.3 million adults in the United States met criteria for an alcohol use disorder 
in the past 12 months. Of those with alcohol use disorders, 2.3 million adults also met 
criteria for a drug use disorder (Stinson et al., 2005) with odds ratios estimated to be 7.4 for 
any drug use disorder, but 3.4 to 19.2 for specific drug use disorders (Khan et al., 2013; 
Stinson et al., 2005). Both alcohol and drug use disorders are heritable, with approximately 
50% of the variance attributable to heritable factors (Bienvenu et al., 2011; Ducci and 
Goldman, 2012; Tsuang et al., 1998; Wang et al., 2012), although this estimate varies 
dramatically by substance (e.g. up to 70% heritability for cocaine dependence)(Kendler et 
al., 2000), age (Bergen et al., 2007; Derringer et al., 2008; Vrieze et al., 2012) and other 
characteristics, including comorbid psychopathology (Pickens et al., 1991).
This heritable variation can be parsed into those genetic influences that are specific to each 
drug and importantly, those genetic factors that confer a general predisposition to alcohol 
and/or substance use disorders, and even other disinhibited behaviors (Hicks et al., 2013; 
Krueger et al., 2002). Two large twin studies have convincingly shown that a preponderance 
of the genetic factors influencing illicit drug use disorders overlap (Kendler et al., 2003; 
Tsuang et al., 2001). Noticeably, when these models were extended to include alcohol use 
disorders, there was evidence for highly correlated genetic factors (r=0.82) that individually 
influenced the covariation in alcohol and nicotine dependence as well as cannabis and 
cocaine dependence (Kendler et al., 2007). The extent of genetic overlap was strong for 
some substances - for instance, 55% and 24% of the genetic variance in alcohol dependence 
was due to the licit and illicit drug factors respectively, with the remainder being substance-
specific. In contrast, for nicotine dependence, 63% of the genetic variance was drug-specific 
(with 26% and 11% attributable to heritable variation in the licit and illicit factors 
respectively). Similar to the individual heritability of each substance, there is growing 
evidence that the heritable covariation across substances changes across development 
(Vrieze et al., 2012; Young et al., 2006). Irrespective of development and substance-specific 
variation, there is broad consensus that gene discovery efforts targeting aggregate genetic 
variation that indexes a shared liability to a variety of substance use disorders, as well as 
disinhibition, can be profitable (McGue et al., 2013; Vrieze et al., 2013a), with one study 
showing evidence for genomewide pleiotropic effects across substance use disorders (Vrieze 
et al., 2013b).
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There are multiple approaches, both phenotypic and genetic, to capture the commonality 
underlying alcohol and substance use disorders and the present study utilizes two 
straightforward phenotypic approaches. We opted for simple dependence-based phenotypic 
traits as they lend themselves to replication and future meta-analysis. First, we utilized a 
binary phenotype, with affection status defined as meeting dependence criteria for at least 
one substance (alcohol, cannabis, cocaine or opioids), termed ANYDEP. Second, we used 
factor analysis to combine dependence criteria across substances into a continuous 
quantitative trait representing vulnerability to multiple substance dependence, termed 
QUANTDEP. This quantitative measure is heritable (approx. 60%) (Palmer et al., 2012) and 
has previously been used in genomic studies (Yang et al., 2012), the most recent of which 
utilized a similar expanded factorial measure of behavioral disinhibition (including alcohol, 
nicotine, cannabis and other illicit drug use disorders) to conduct genomewide association 
and rare nonsynonymous variant analyses (McGue et al., 2013; Vrieze et al., 2013a). These 
studies did not identify any single common or rare variant at a genomewide significant level; 
however, the authors reported that 84% of the heritability in illicit drug use was explained 
by both common and rare variants. While the work of McGue and colleagues included 
multiple measures of nicotine use and dependence, we elected to exclude nicotine from 
these measures of general liability based on the work by Kendler and colleagues (Kendler et 
al., 2007), which showed significant drug-specific genetic influences on nicotine 
dependence.
In this study, we utilized data from 2,322 subjects from 118 families of European-American 
descent ascertained for alcohol dependence liability to conduct genomewide association 
analysis of a binary and a continuous index of general substance dependence liability. While 
some prior genomewide efforts (McGue et al., 2013) have utilized similar phenotypes in 
population samples of related individuals, the ascertainment strategy and extended family-
based design in our study should increase our ability to detect genetic variation in this 
phenotype. First, there is substantial evidence that alcohol use disorders that co-aggregate 
with other substance use disorders (Khan et al., 2013) may represent a more heritable form 
of addiction (Pickens et al., 1991). Secondly, by modeling the strength of the phenotypic 
correlation across different degrees of genetic relatedness (i.e. kinship), we utilize data on all 
related individuals, even those not meeting criteria for diagnoses, allowing us to better 
explore the extent of co-aggregation of genetic risk across alcohol, cannabis, cocaine and 
opioid dependence.
Materials and methods
Sample
Six sites participating in the Collaborative Study on the Genetics of Alcoholism (COGA) 
(Begleiter et al., 1995; Foroud et al., 2000) recruited alcohol dependent probands from 
inpatient and outpatient facilities. The probands and their family members were 
administered a poly-diagnostic interview, the Semi-Structured Assessment for the Genetics 
of Alcoholism (SSAGA) (Bucholz et al., 1994; Hesselbrock et al., 1999). Individuals 17 
years of age or younger were administered an adolescent version of the SSAGA. 
Institutional review boards at all sites approved the study.
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A subset of the most genetically informative families was selected for a family-based 
genome-wide association analysis (GWAS). This sample has been described in detail 
elsewhere (Kang et al., 2013; Wang et al., 2013) but salient characteristics are presented 
here. Families were prioritized based on the number of family members with: (1) available 
DNA who were also alcohol dependent, (2) available DNA who also had electrophysiology 
data, and (3) available DNA, regardless of other phenotypes. To reduce heterogeneity, only 
families consisting primarily of self-reported European American ethnicity were included in 
the sample. The final sample was comprised of 118 large European American families 
consisting of 2,322 individuals with available DNA.
Phenotypes and Statistical Analysis
Phenotype data for four substances (alcohol, cannabis, cocaine, and opioids) were obtained 
from the SSAGA. Some individuals were assessed more than once, in which case data from 
the SSAGA interview at which an individual reported the maximum number of DSM-IV 
criteria endorsements for the particular substance was used. Two phenotypes were used in 
the genetic analyses: ANYDEP, a binary aggregate substance dependence phenotype, and 
QUANTDEP, a quantitative (continuous) substance dependence phenotype developed using 
factor analysis.
For ANYDEP, individuals were considered affected if they met DSM-IV lifetime 
dependence criteria for any of the 4 substances, and unaffected if they did not meet DSM-IV 
dependence criteria for all 4 drugs. Individuals younger than 23 years old at their most 
recent interview who did not meet criteria for dependence on any of the 4 drugs were 
recoded to missing/unknown (n=408) because they had not passed through the primary age 
of risk. Selection of this age cutoff was based on the median age of onset of alcohol, 
cannabis, cocaine and opioid/heroin dependence in the White subsample of the U.S. 
population based National Epidemiologic Survey of Alcohol and Related Conditions 
(NESARC) (Grant et al., 2004; Hingson et al., 2006). The median ages ranged from 18-22 
years, supporting a cutoff of 23 years. In addition, those individuals with insufficient 
SSAGA to determine whether they were or were not dependent were also coded as unknown 
(n=144).
QUANTDEP, the quantitative factor score, was constructed by conducting a confirmatory 
factor analysis of the 7 DSM-IV lifetime dependence criteria (coded as present or absent) for 
each of the 4 substances (28 items total). As we were interested in those genetic 
underpinnings that were common to all dependence criteria across the four substances, we 
elected to use a single factor confirmatory model and did not conduct exploratory analyses, 
in addition to limiting the factor analysis to the dependence criteria to exclude abuse. All 
individuals with DSM-IV criteria data were utilized, regardless of age, or substance use. The 
factor score from the resulting confirmatory analyses was utilized as the quantitative 
phenotype.
Heritability was estimated for the two phenotypes using the polygenic option in SOLAR 
(Almasy and Blangero, 1998). The correlation between the total number of DSM-IV criteria 
endorsed (between 0 and 28) and QUANTDEP was estimated using the Pearson correlation 
coefficient. Analysis of variance (ANOVA) was used to test if QUANTDEP differed 
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according to the number of substance dependence diagnoses met. We also tested if the 
average QUANTDEP value differed across alcohol, cannabis, cocaine and opioid 
dependence diagnoses. Post-hoc pairwise comparisons employed a Tukey correction for 
multiple testing.
Genotyping and Association Analysis
Genotyping for 2,105 subjects in these 118 families was performed at the Genome 
Technology Access Center at Washington University School of Medicine in St. Louis using 
the Illumina Human OmniExpress array 12.VI (Illumina, San Diego, CA, USA). In addition, 
genotypes previously generated on the Illumina Human 1M-Duo BeadChip (Illumina, San 
Diego, CA, USA) by the Center for Inherited Disease Research were included for 224 
subjects from these families (Edenberg et al., 2010). Further details describing data cleaning 
can be found in Wetherill et al. (Wetherill et al., 2014). The final analytic sample included 
2,322 genotyped individuals. This yielded an average of 19.6 genotyped members per 
family.
The Genome-Wide Association Analysis with Family Data package was utilized to analyze 
ANYDEP, implemented as a logistic regression model. Relatedness between family 
members was accounted for via generalized estimating equations. QUANTDEP was 
analyzed using a linear mixed effects model as implemented in the kinship library (lmekin) 
in R (http://www.inside-r.org/packages/cran/kinship/docs/print.lmekin). This model in the 
kinship function allows for the covariance matrix to be completely specified for the random 
effects. The result is that each family has a different covariance pattern based on the kinship 
coefficients, to model the familial genetic random effects. Gender and birth cohort defined 
by year of birth (<1930, 1930-1949, 1950-1969, and ≥1970), were included as covariates in 
all analyses described above, including statistical models of association, to account for 
secular trends (Grucza et al., 2008). As needed, genomic control was applied to correct for 
inflation. To reduce the scope of multiple testing, only genotyped SNPs were included in the 
initial analyses. After correcting for the final number of autosomal SNPs (n=591,785), the 
genome-wide significance threshold was p=8.45×10−8.
In regions with significant association results, we analyzed imputed SNPs to further evaluate 
the evidence for association. SNPs were imputed to 1000 Genomes (EUR, August 2010 
release) using BEAGLE 3.3.1 (Browning and Browning, 2009) as described in Wang et al 
(Wang et al., 2013). Secondary analyses were performed for significant SNPs to test 
whether the observed genetic association could be attributed to dependence on a specific 
substance. Analyses for ANYDEP were performed using the Mantel-Haenszel Chi-Square 
test of association assuming an additive genetic model. Analyses for QUANTDEP were 
performed using analysis of covariance employing substance, genotype, and the 
substance*genotype interaction to test for differences in genotype by substance. Gender and 
birth cohort were included as covariates.
Replication Study
Independent replication of SNPs demonstrating evidence of significant association in the 
COGA sample was evaluated in the Study of Addiction: Genetics and Environment (SAGE) 
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sample. SAGE is a case-control sample comprised of three complementary studies: COGA, 
the Family Study of Cocaine Dependence and the Collaborative Genetics Study of Nicotine 
Dependence (Bierut, 2010). There were 129 individuals from the 118 COGA families in the 
current study that overlapped with the SAGE sample, and were removed from the SAGE 
replication dataset. The remaining independent SAGE sample used for replication was 
limited to 2,647 individuals of European American descent. Factor analysis scores from 
Mplus were independently estimated for this study, as described above, based on DSM-IV 
dependence criteria for the 4 substances. Analyses were implemented in Plink and included 
age at interview and gender as covariates.
RESULTS
ANYDEP
The number of individuals utilized for the categorical phenotype ANYDEP was 1,770 (59% 
male). Summary results are provided only for genotyped individuals for both phenotypes. 
Nearly half the sample met DSM-IV criteria for at least one substance (ANYDEP, N=832, 
47%). The COGA sample was ascertained through an alcohol dependent individual in 
treatment and families were selected for the highest density of alcohol dependent members; 
therefore, it was expected that there would be many individuals meeting criteria for alcohol 
dependence (40% in the full sample, but 84% of those who were dependent on alcohol 
and/or any other substance). In addition, 19% met criteria for cannabis dependence (with or 
without alcohol dependence). The rates for cocaine and opioid dependence were lower (11% 
and 4% respectively). There were 832 individuals that met criteria for at least one substance 
dependence diagnosis; of those, 312 (37.5%) endorsed at least two diagnoses. Alcohol and 
cannabis dependence were the most common (15%; Table 1).
QUANTDEP
The number of individuals included in the analysis of the quantitative factor score 
QUANTDEP was 2,183 (47% male). The confirmatory one factor model fit the data well in 
COGA (CFI=0.96; RMSEA=0.07) and in the replication sample, SAGE (CFI=0.98; 
RMSEA=0.07), supporting our proposed unidimensional conceptualization of dependence 
criteria for alcohol, cannabis, cocaine and opioids. Factor loadings in the COGA sample 
ranged from 0.67 (alcohol dependence criterion desire to cut down) to 0.99 (for several 
cocaine dependence criteria) and were highly consistent across COGA and SAGE. In 
general, factor loadings for alcohol and cannabis dependence criteria were lower, and ranged 
between 0.67-0.85 while those for cocaine and opioids were uniformly high (0.84-0.99). 
Data across drug classes and across criteria loadings (and standard errors) for all 7 criteria 
for the 4 substances are available in Supplemental Material Figure 1.
ANYDEP and QUANTDEP
As expected, individuals with no substance dependence had the lowest QUANTDEP values 
(mean = −0.40, standard error (se) = 0.01) and those with a dependence diagnosis for all 4 
substances had the highest QUANTDEP values (mean = 1.45, se = 0.06; overall 
F(8,1762)=659.4, p<0.0001; all pairwise Tukey-adjusted p<0.006) (Figure 1A). 
QUANTDEP values differed based on the substance (overall F(7,502)=32.9, p<0.0001; all 
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pairwise Tukey-adjusted p<0.03), with individuals meeting cocaine dependence criteria 
having the highest mean QUANTDEP scores and those meeting criteria for alcohol 
dependence having the lowest (Figure 1B) of individuals meeting criteria for dependence on 
any substance. QUANTDEP was positively correlated with the total number of DSM-IV 
criteria endorsed across the 4 substances (rho = 0.88, p<0.0001).
Genetic Analysis—The ANYDEP phenotype was moderately heritable, with an estimate 
of 0.54 (standard error = 0.08, p=1.3×10−17). Heritability for the QUANTDEP was higher, 
with an estimate of 0.86 (standard error = 0.02, p=2.1−10−66).
Association analyses results are summarized in Figure 2. All association results with 
p<1.0×10−6 are shown in Table 2. More extensive results are provided in Supplemental 
Table 1. The QQ plot for ANYDEP revealed inflation of p-values (λ = 1.0608); therefore 
Genomic Control (GC) p-values were calculated. The lambda for the inflation-corrected p-
values = 0.99999, indicating no further inflation. All p-values reported for ANYDEP are GC 
p-values. There was no evidence to suggest inflation of the association p-values for 
QUANTDEP (QUANTDEP λ = 1.0095). QQ plots are provided for each phenotype 
(Supplemental Figure 2).
Two genotyped SNPs reached genome-wide significance (p<8.4 × 10−8). A SNP in the 
uncharacterized gene LOC151121 on chromosome 2, rs2952621, was associated with 
ANYDEP (p=1.8×10−8; OR = 1.07). Secondary analysis was performed to test whether this 
SNP demonstrated greater evidence of association with a particular substance. Although 
more individuals were alcohol dependent, the pattern of dependence by genotype was 
similar for all 4 substances (χ(1)2 = 0.48, p=0.49; Figure 3A), indicating that the association 
was not driven by dependence on one particular substance. Individuals with one or two 
copies of the minor allele (T) were more likely to be dependent on at least one substance 
than those having no copies of the minor allele. Analysis of imputed SNPs in this region 
provided additional evidence to support the association (Figure 4A). There was modest 
replication for this SNP in the SAGE sample (p=0.02, OR = 1.1), with T as the risk allele in 
both samples. Corresponding SAGE results for the SNPs are provided in Table 2.
The second genome-wide significant finding was observed with QUANTDEP and a 
genotyped SNP rs2567261 on chromosome 18 in the gene ARHGAP28 (Rho GTPase 
activating protein 28) (p=3.8×10−8). Due to the low minor allele frequency for this SNP 
(MAF=0.08), AA and AG genotypes were combined. Although individuals dependent on 
opioids and cocaine had higher QUANTDEP scores on average (main effect of substance 
p<0.0001; Figure 3B), there was no substance*genotype effect (p=0.74) confirming that 
QUANTDEP exhibited the same pattern by genotype across the 4 substances. Analysis of 
the imputed SNPs in this region further supported the association (Figure 4B). There was no 
evidence of replication in SAGE for QUANTDEP (p=0.29). Corresponding SAGE results 
for the SNPs are provided in Table 2.
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DISCUSSION
This is one of the first GWAS to test for the association of overall substance dependence 
phenotypes, defined both categorically (dependence diagnosis for alcohol, cannabis, cocaine 
or opioids; ANYDEP) and quantitatively (factor analysis of the 7 DSM-IV dependence 
criteria, across alcohol, cannabis, cocaine and opioids; QUANTDEP). This approach 
implicitly tested the hypothesis that there are genes with pleiotropic effects contributing to 
dependence on alcohol, cannabis, cocaine and opioids. Using these multi-substance 
phenotypes, we detected genome-wide significant results with SNPs in two different genes. 
This finding is consistent with an extensive twin literature that provides demonstrable 
support for common genetic liability underlying addiction to multiple substances (Kendler et 
al., 2003; Tsuang et al., 2001). Furthermore, a previous study in a slightly different COGA 
sample demonstrated aggregation of drug dependence in relatives of alcohol-dependent 
probands, even after controlling for comorbidity in the probands (Nurnberger et al., 2004).
Genomewide significant association for ANYDEP was observed with a SNP in an 
uncharacterized gene, LOC151121 (p=1.8×10−8). Further evidence of association was 
corroborated by surrounding SNPs, both genotyped and imputed. Nominal replication was 
found in the SAGE sample (p=0.02) with the same phenotype. This SNP was moderately 
associated with QUANTDEP (p=3.8 ×10−5) and also with the number of DSM-IV alcohol 
dependence criteria endorsed (symptom count) in another related study with data from the 
same sample (p=7.2×10−5), (Wang et al., 2013). Similar to the replication results here, this 
SNP was nominally associated with the alcohol dependence symptom count in the SAGE 
sample as well (p=0.014) (Wang et al., 2013).
Significant association was also detected with QUANTDEP for the SNP rs2567261 in 
ARHGAP28 (p=3.8×10−8). Further evidence of association was observed with both 
genotyped and imputed SNPs within the gene. ARHGAP28 is also known as Rho GTPase 
activating protein 28. GTPase-activating proteins target GTPases, and are mediated by 
exposure to alcohol, cannabis, cocaine, and opioids. For example Rho1 and Rac moderate 
the stimulating and sedative effects of acute ethanol intoxication in Drosophila (Rothenfluh 
et al., 2006). Thus, there is strong biological rationale for this gene as a potential candidate 
for substance dependence. Of note, this SNP was modestly associated with ANYDEP 
(p=3.2×10−4) in this sample and with previously published alcohol symptom count in the 
COGA family sample (p=8.7×10−5). However, rs2567261 was not significantly associated 
with alcohol symptom count in the SAGE sample, although there was a trend in that 
direction (p=0.08) (Wang et al., 2013). Although the association did not replicate in the 
SAGE sample for this phenotype, there was a trend towards association with the other 
phenotype, ANYDEP (p=0.08). This weak replication for a different phenotype may be due 
to the fact that the majority of the SAGE sample was ascertained on nicotine and cocaine 
dependence, whereas the COGA sample was recruited based on an alcohol dependent 
proband and expanded to include the maximum number of alcohol dependent family 
members. The exclusion of nicotine dependence criteria may have attenuated the likelihood 
of replication, given ascertainment for nicotine dependence in SAGE. Since the SNP 
association was not primarily due to alcohol dependence, it is possible that high rates of 
comorbidity in the COGA sample as compared with the SAGE sample contributed to the 
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finding. In addition, the family-based test in the large COGA families with comorbidity may 
have had greater power to detect the association. QUANTDEP seems to represent an 
underlying severity of addiction. As seen in Figure 3A, the higher the number of comorbid 
diagnoses, the higher the QUANTDEP scores.
Overall, for the QUANTDEP measure, the loadings for the alcohol and cannabis criteria 
appear generalizable to general population studies (Lynskey and Agrawal, 2007; Saha et al., 
2006); in contrast, those for cocaine and opioid dependence are higher (typically > 0.9). In 
COGA, cocaine (7-12%) and opioid (2-5%) dependence criteria were less commonly 
endorsed than those for alcohol (15-51%) and cannabis (9-19%), with the former also 
showing less range in endorsement rates (i.e. each dependence criterion was equally likely to 
be endorsed). In SAGE, cocaine dependence criteria (17-19%) were somewhat more 
commonly endorsed than cannabis (12-18%) dependence criteria, yet the cocaine criteria 
had higher loadings than the cannabis criteria, identical to COGA. For both cocaine and 
opioids, the range of prevalence of individual criteria was highly restricted (e.g. 6-7% for 
opioid criteria). Thus, in both COGA and SAGE, the likelihood of endorsement of each of 
the 7 dependence criteria for cocaine and opioids was similar while certain alcohol and 
cannabis criteria (e.g. tolerance) were endorsed more often than others (e.g. use dominates 
life). This may be related to the ascertainment strategy and overrepresentation of family 
history for alcoholism in both samples. Nonetheless, all factor loadings were high, indicating 
that QUANTDEP reflects a general liability to dependence across multiple substances. In 
particular, QUANTDEP captures the liability to cocaine and opioid dependence criteria in 
these two studies. Therefore, in addition to being an index of severity and a measure of 
general liability to addiction across alcohol and drugs, QUANTDEP likely also reflects 
variation in prevalence and the expected pattern of comorbid relationships and co-
aggregation across alcohol and drug dependence criteria in these subjects ascertained on 
specific substance dependence.
While the heritability of the binary phenotype of dependence on any substance was similar 
in this sample (h2=0.54) to the most common heritability estimate (h2=0.50) reported for any 
of the four substances from twin studies (Goldman et al., 2005), the heritability for the 
quantitative phenotype was much higher (h2=0.86). This is consistent with one prior twin 
study of a latent genetic factor (h2=0.81) underlying alcohol and drug problems as well as 
measures of impulsivity and conduct problems (Krueger et al., 2002) but significantly higher 
than some others (e.g. h2=0.40) (Button et al., 2009). Although this high heritability should 
not be over-interpreted (Goldman et al., 2005), it is possible that the use of a multi-variable 
quantitative phenotype, utilizing the pattern of endorsement of the 7 DSM-IV criteria across 
all four substances, captured valuable genetic information across the vulnerability spectrum.
The two phenotypes used in this study were both aggregate measures of overall dependence. 
Although their top genetic signals did not overlap (i.e. the same SNP did not reach statistical 
significance for both phenotypes), there was evidence of association for the other phenotype 
for the two SNPs that attained genomewide significance (see Supplemental Table 1 for 
additional comparisons). The difference in magnitude of p-value is not surprising given the 
arguable validity of the diagnostic cutoff (i.e. 3 or more of 7 dependence criteria) 
implemented in DSM-IV which likely excluded from affected status (for ANYDEP), a 
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number of individuals who may have met criteria for abuse or endorsed 1-2 dependence 
symptoms across one or even multiple drugs, and thus did not qualify for dependence. 
Viewed alternatively, the unaffected individuals for ANYDEP represent a heterogeneous 
group varying in severity. Such variability was better captured by QUANTDEP, which 
while not taking abuse criteria into account, was a better approximation of the range of 
vulnerability to substance-related problems. Thus, it is likely that ANYDEP reflects the 
more severe of the QUANTDEP scores. Finally, the possibility that our findings reflect false 
positives cannot be excluded.
There have been multiple prior GWAS that have utilized symptom counts and factor scores 
of alcohol dependence criteria (Vrieze et al., 2013a; Yang et al., 2012) but only one 
attempted to combine indices of alcohol (consumption and dependence), nicotine and drug 
misuse (with disinhibition measures) using hierarchical factorial analyses for GWAS. In that 
study, McGue and colleagues (McGue et al., 2013) reported on 4 SNPs associated with 
multiple first order (e.g. alcohol consumption, alcohol dependence, illicit drug dependence) 
and higher order externalizing factors. One of these SNPs, rs10037670 in GALNT10, with 
the highest association for illicit drug dependence factor (p=3.8×10−6) was modestly 
associated in this study with both ANYDEP (p=0.0029) and QUANTDEP (p=0.0067).
There are several strengths of this study design, the first being the use of families densely 
affected with alcohol dependent individuals. Family (Merikangas et al., 1998; Nurnberger et 
al., 2004) and twin (Tsuang et al., 1998) studies suggest familial co-aggregation and 
heritable overlap across alcohol, cannabis, cocaine and opioids. Thus, this family-based 
COGA sample, enriched for dependence on multiple substances and shared genetic risk, 
allowed us to test for the association of common variants with risk for dependence across 
multiple substances. A second strength of this study was the use of a family-based 
association design. This allowed us to examine association within a family consisting of 
members who endorsed criteria for dependence on different (or multiple) substances. Third, 
family-based analysis is robust to population substructures such as nuanced differences in 
ethnicity, which might occur with marry-in individuals of a different race, and in turn affects 
the genetic diversity of the offspring.
Three caveats are worth considering. First, only a small subset of individuals met DSM-IV 
criteria for opioid and cocaine dependence. Thus, it is possible that results pertain more 
closely to lower liabilities to these substances. Second, we did not include nicotine 
dependence criteria in this analysis. As we were interested in a confirmatory model of 
unidimensional genetic risk, we elected to exclude nicotine symptoms based on published 
evidence for a preponderance of non-overlapping genetic influences on these criteria. 
Finally, we elected not to utilize abuse criteria (nor craving), despite DSM-5 related 
changes. Previous findings in COGA families demonstrated that abuse did not aggregate in 
relatives of alcohol dependent probands (Nurnberger et al., 2004). In addition, the extant 
psychometric literature suggests that with the exception of hazardous use which is 
frequently endorsed to the exclusion of other abuse or dependence criteria, the remaining 
abuse criteria (failure to fulfill role obligations and social/interpersonal problems) and 
craving are infrequently endorsed in the absence of co-occurring dependence criteria. This is 
particularly true in samples ascertained for substance use disorders, such as SAGE and 
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COGA. For instance, in SAGE, of those who reported no alcohol dependence criteria, only 
12-26 individuals endorsed at least one abuse criterion other than hazardous use (which was 
endorsed by 140). Hence, it is unlikely that the exclusion of abuse criteria resulted in our 
inability to capture a relevant portion of the liability continuum.
In summary, this study provides evidence that there are common variants that contribute to 
the risk for a general liability to substance dependence, defined qualitatively and 
quantitatively. The results of this study require replication in independent samples to further 
explore whether overall dependence on multiple or individual substances is associated with 
the SNPs in these regions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Mean and standard error of ANYQUANT scores for individuals used in analysis based on: 
Number of substance dependence diagnoses; B. Each DSM-IV substance dependence 
endorsed (includes comorbidities)
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Figure 2. 
Association results: A. ANYDEP, genomic-control p-values; B. QUANTDEP.
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Figure 3. 
Sample characterization by SNP genotype. A: Dependence on each substance by genotype 
of rs2952621 in LOC151121 for all individuals meeting criteria for alcohol, cannabis, 
cocaine, and opioid dependence; 3B: Mean QUANTDEP by genotype of rs2567261 in 
ARHGAP28 for all individuals meeting criteria for alcohol, cannabis, cocaine, and opioid.
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Figure 4. Association results
A. ANYDEP with genotyped and imputed SNPs in the region flanking LOC151121; Y-axis 
denotes the −log10(p-value) for association. X-axis is the physical position on the 
chromosome (Mb). The most significantly associated SNP is shown in purple. The extent of 
linkage disequilibrium (as measured by r2) between each SNP and the most significantly 
associated SNP is indicated by the color scale at top right. Larger values of r2 indicate 
greater linkage disequilibrium. Genotyped SNPs are indicated as circles, and imputed SNPs 
by squares. B. QUANTDEP with genotyped and imputed SNPs in the region flanking 
ARHGAP28. Y-axis denotes the −log10(p-value) for association. X-axis is the physical 
position on the chromosome (Mb). The most significantly associated SNP is shown in 
purple. The extent of linkage disequilibrium (as measured by r2) between each SNP and the 
most significantly associated SNP is indicated by the color scale at top right. Larger values 
of r2 indicate greater linkage disequilibrium. Genotyped SNPs are indicated as circles, and 
imputed SNPs by squares.
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Table 1
Substance Dependence for the 832 genotyped individuals meeting any criteria for DSM-
IV substance dependence
SUBSTANCE # Affected % Affected of all affected
 ANY Alcohol* 696 83.6
 ANY Cannabis* 331 39.7
 ANY Cocaine* 182 22.4
 ANY Opioids* 72 8.9
PATTERNS OF SUBSTANCE DEPENDENCE
COMORBIDITY
 Alcohol Alone 405 48.7
 Cannabis Alone 85 10.2
 Cocaine Alone 23 2.8
 Opioids Alone 7 0.8
 Alcohol + Cannabis 126 15.1
 Alcohol + Cocaine 40 4.8
 Alcohol + Opioids 15 1.8
 Cannabis + Cocaine 14 1.7
 Cannabis + Opioids 2 0.2
 Cocaine + Opioids 1 0.1
 Alcohol + Cannabis + Cocaine 67 8.0
 Alcohol + Cannabis + Opioids 10 1.2
 Alcohol + Cocaine + Opioids 10 1.2
 Cannabis + Cocaine + Opioids 4 0.5
 Alcohol + Cannabis + Cocaine + Opioids 23 2.8
Total 832 100%
*includes comorbid individuals
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